Nautilus Biotechnology Company Insiders

Nautilus Biotechnology Management Team Effectiveness

The company has return on total asset (ROA) of (0.1857) % which means that it has lost $0.1857 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2986) %, meaning that it created substantial loss on money invested by shareholders. Nautilus Biotechnology's management efficiency ratios could be used to measure how well Nautilus Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.28 in 2025. Return On Capital Employed is likely to drop to -0.24 in 2025. Liabilities And Stockholders Equity is likely to gain to about 243 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 5.2 M in 2025. Common Stock Shares Outstanding is likely to drop to about 79.2 M in 2025. Net Loss is likely to drop to about (54.7 M) in 2025

Nautilus Biotechnology Workforce Comparison

Nautilus Biotechnology Insider Trading

Nautilus Biotechnology Notable Stakeholders

The success or failure of an entity such as Nautilus Biotechnology often depends on how effective the management is. Nautilus Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nautilus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nautilus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Nautilus Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nautilus Biotechnology. Check Nautilus Biotechnology's Beneish M Score to see the likelihood of Nautilus Biotechnology's management manipulating its earnings.

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.